Mutant selectivity remains one of drug discovery’s hardest problems. New preclinical research applying quantum chemistry to JAK2V617F illustrates how detailed molecular analysis can inform more selective inhibitor design.

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.

Researchers have discovered that reorganising a single cancer-targeting peptide within a spherical nucleic acid vaccine dramatically boosts the immune system’s ability to attack HPV-driven tumours.

A herb called Launaea nudicaulis could be used to treat peptic ulcers, with early research suggesting both gastroprotective benefits and potential applications in natural product drug discovery.

A new platform from Promega enables scientists to measure compound binding directly in living cells, helping to translate biochemical hits into more reliable drug discovery decisions.

For International Day of Women and Girls in Science, Drug Target Review highlights articles published over the past year that were authored by women, celebrating their contributions to research.

A new SHANK3 conditional knockout mouse model from InnoSer, CureSHANK and Ozgene has been launched to advance research into Phelan-McDermid syndrome, other neurodevelopmental disorders and the development of new therapies.

A new US-based company has launched with the aim of tackling one of the most persistent operational challenges in modern drug discovery – the slow and fragmented handling of physical compounds.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.